Effect of alogliptin , a DPP-4 inhibitor, on markers of lipid metabolism in type 2 diabetic patients

Effect of alogliptin , a DPP-4 inhibitor, on markers of lipid metabolism in type 2 diabetic patients - Effect of alogliptin , a DPP-4 inhibitor, on markers of lipid metabolism in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011470

Enrollment

Registered

2013-08-13

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetic patients

Interventions

alogliptin 25 mg/day was administered for eight weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: taking oral hypoglycemic agents and had HbA1c levels of 6.9% or higher for three months or longer.

Exclusion criteria

Exclusion criteria: patients receiving insulin therapy; severe liver or renal dysfunction; patients with hypersensitivity to alogliptin; patients that had their hypoglycemic agents changed within three months; pregnant women or breast-feeding mothers; and excessive alcohol drinkers.

Design outcomes

Primary

Measure	Time frame
Change of Apo protein,Apo B Apo-A1,after 8 weeks	—

Countries

Japan

Contacts

Public ContactYuzuru Kishitani

Nara Hospital Kinki University Faculty of Medicine Gastroenterology, Endocrinology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026